Search
Innoviva Inc
INVAAdd to Watchlist
21.970USD
-0.890-3.89%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
1.62BMarket Cap
3.02P/E TTM
More Details of Innoviva Inc Company
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Innoviva Inc Info
Ticker SymbolINVA
Company nameInnoviva Inc
IPO dateOct 05, 2004
CEORaifeld (Pavel)
Number of employees127
Security typeOrdinary Share
Fiscal year-endOct 05
Address1350 Old Bayshore Highway
CityBURLINGAME
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94010
Phone16502389600
Websitehttps://www.inva.com/
Ticker SymbolINVA
IPO dateOct 05, 2004
CEORaifeld (Pavel)
Company Executives of Innoviva Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Pavel Raifeld
Mr. Pavel Raifeld
Chief Executive Officer
Chief Executive Officer
147.47K
+85.88%
Dr. Sarah J. Schlesinger, M.D.
Dr. Sarah J. Schlesinger, M.D.
Lead Independent Director
Lead Independent Director
140.49K
+6.97%
Mr. Stephen Basso
Mr. Stephen Basso
Chief Financial Officer
Chief Financial Officer
46.42K
+81.84%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
44.10K
+10.69%
Ms. Marianne Y. Zhen, CPA
Ms. Marianne Y. Zhen, CPA
Chief Accounting Officer
Chief Accounting Officer
42.98K
+29.70%
Dr. Odysseas D. Kostas, M.D.
Dr. Odysseas D. Kostas, M.D.
Director
Director
--
--
Mr. Mark A. Dipaolo, Esq.
Mr. Mark A. Dipaolo, Esq.
Chairman of the Board
Chairman of the Board
--
--
Mr. Jules A. Haimovitz
Mr. Jules A. Haimovitz
Independent Director
Independent Director
--
--
Mr. Derek A Small
Mr. Derek A Small
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Pavel Raifeld
Mr. Pavel Raifeld
Chief Executive Officer
Chief Executive Officer
147.47K
+85.88%
Dr. Sarah J. Schlesinger, M.D.
Dr. Sarah J. Schlesinger, M.D.
Lead Independent Director
Lead Independent Director
140.49K
+6.97%
Mr. Stephen Basso
Mr. Stephen Basso
Chief Financial Officer
Chief Financial Officer
46.42K
+81.84%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
44.10K
+10.69%
Ms. Marianne Y. Zhen, CPA
Ms. Marianne Y. Zhen, CPA
Chief Accounting Officer
Chief Accounting Officer
42.98K
+29.70%
Dr. Odysseas D. Kostas, M.D.
Dr. Odysseas D. Kostas, M.D.
Director
Director
--
--
Revenue Breakdown
FY2025
FY2025Q4
FY2025Q2
FY2025Q1
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
411.33M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.82%
Dimensional Fund Advisors, L.P.
6.01%
Vanguard Portfolio Management, LLC
5.72%
Renaissance Technologies LLC
5.70%
Vanguard Capital Management, LLC
4.26%
Other
65.48%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.82%
Dimensional Fund Advisors, L.P.
6.01%
Vanguard Portfolio Management, LLC
5.72%
Renaissance Technologies LLC
5.70%
Vanguard Capital Management, LLC
4.26%
Other
65.48%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.53%
Investment Advisor/Hedge Fund
36.28%
Hedge Fund
17.14%
Research Firm
4.45%
Bank and Trust
3.55%
Pension Fund
1.68%
Individual Investor
0.97%
Family Office
0.04%
Insurance Company
0.03%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
573
80.96M
109.69%
-4.36M
2025Q4
539
80.86M
108.15%
-1.92M
2025Q3
506
75.62M
101.14%
-2.32M
2025Q2
497
69.38M
110.09%
-7.80M
2025Q1
503
69.52M
110.75%
-9.29M
2024Q4
492
73.18M
116.75%
-6.44M
2024Q3
487
75.41M
120.47%
-5.51M
2024Q2
492
75.89M
121.41%
-5.03M
2024Q1
502
75.85M
119.80%
-4.18M
2023Q4
494
74.97M
116.88%
-1.82M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
9.46M
12.78%
+1.13M
+13.53%
Dec 31, 2025
Dimensional Fund Advisors, L.P.
4.36M
5.89%
+30.05K
+0.69%
Dec 31, 2025
Renaissance Technologies LLC
4.21M
5.69%
-376.76K
-8.21%
Dec 31, 2025
Sarissa Capital Management, L.P.
2.82M
3.8%
--
--
Dec 31, 2025
State Street Investment Management (US)
2.80M
3.78%
+239.85K
+9.38%
Dec 31, 2025
Arrowstreet Capital, Limited Partnership
2.36M
3.18%
-898.00
-0.04%
Dec 31, 2025
American Century Investment Management, Inc.
2.24M
3.02%
-111.26K
-4.73%
Dec 31, 2025
Bank of Nova Scotia
2.18M
2.94%
-1.41M
-39.23%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Pharmaceuticals ETF
2.44%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.33%
State Street SPDR S&P Pharmaceuticals ETF
2.27%
ETC 6 Meridian Small Cap Equity ETF
2.06%
Vanguard US Minimum Volatility ETF
1.64%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.06%
Invesco S&P SmallCap Low Volatility ETF
0.91%
Acquirers Small and Micro Deep Value ETF
0.9%
Invesco S&P SmallCap Health Care ETF
0.67%
VictoryShares US Small Mid Cap Value Momentum ETF
0.59%
View more
Invesco Pharmaceuticals ETF
Proportion2.44%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.33%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.27%
ETC 6 Meridian Small Cap Equity ETF
Proportion2.06%
Vanguard US Minimum Volatility ETF
Proportion1.64%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion1.06%
Invesco S&P SmallCap Low Volatility ETF
Proportion0.91%
Acquirers Small and Micro Deep Value ETF
Proportion0.9%
Invesco S&P SmallCap Health Care ETF
Proportion0.67%
VictoryShares US Small Mid Cap Value Momentum ETF
Proportion0.59%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
